Welcome to our dedicated page for Mynd Life Scienc news (Ticker: MYNDF), a resource for investors and traders seeking the latest updates and insights on Mynd Life Scienc stock.
News and updates for MYND Life Sciences Inc. (MYNDF) reflect its activities as a clinical-stage life sciences and medical biotech drug research and development company. The company’s news releases describe a focus on neuro-pharmaceutical and novel drug development, diagnostics, and vaccines, with particular emphasis on depression and inflammation-related diseases.
Recent announcements highlight MYND’s efforts to develop and commercialize a proprietary biomarker test for depression, including Major Depressive Disorder (MDD) and treatment-resistant depression (TRD). The company has discussed the MYND Anti-Inflammatory Peptide (MAP) test, which it describes as a biomarker aimed at diagnosing and monitoring depression by tracking neuroinflammation. News items often emphasize the goal of bringing a depression-focused biomarker test to market and the potential for this proprietary biomarker to support personalized patient management strategies.
Company news also covers corporate and financial developments, such as proposed share issuances to remove or restructure debt, shares-for-debt agreements, and other balance sheet changes. These disclosures explain how MYND is addressing outstanding indebtedness and debentures through the issuance of common shares, including transactions involving related parties under Canadian securities rules.
Regulatory and governance updates form another important category of news. MYND has reported on a management cease trade order (MCTO) granted under National Policy 12-203 due to delays in filing annual financial statements linked to significant restructuring of its debt and equity. The company’s news releases describe the scope of the MCTO, its impact on insiders, and the requirement to issue periodic default status reports.
Visitors to this page can review MYND Life Sciences’ historical and ongoing disclosures about its depression biomarker work, neuro-pharmaceutical research, capital structure changes, and regulatory reporting status, as presented in its official news releases.
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTC: RVLWF) has signed a binding letter of intent with MYND Diagnostics Inc. for a clinical research collaboration. This aims to study the relationship between diagnostic results using MYND's proprietary anti-inflammatory peptide biomarker (MAP) and improved patient outcomes in mental health. The initial clinical trials will focus on patients with post-COVID-19 mental health symptoms, utilizing Revitalist's network of over 2,300 patients. The goal is to submit MAP to the FDA for approval in Q2 2022, enhancing diagnostic accuracy and treatment efficacy.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announces a binding LOI with Revitalist Lifestyle and Wellness to collaborate on clinical research. This partnership aims to study the MAP biomarker’s effectiveness in diagnosing and monitoring mental health, particularly in patients experiencing post-COVID-19 symptoms like 'Brain Fog.' The objective is to provide a more objective diagnostic tool for healthcare providers and to gain FDA approval by Q2 2022. MYND anticipates generating revenue through research and aims to expand its mental health studies leveraging Revitalist's extensive clinic network.
MYND Life Sciences Inc. has announced significant changes to its Board of Directors. Aaron Bowden, a founding board member, has resigned, with the company expressing gratitude for his contributions. In his place, Scott L. Nicoll has been appointed as an independent director and interim Chair of the Audit Committee. Nicoll brings extensive legal and governance experience as a partner at Panorama Legal LLP and chair of Food Banks BC. The board is optimistic that his leadership will enhance the company's governance.
MYND Life Sciences (CSE: MYND, OTC: MYNDF) announced its agreement to acquire intellectual property rights from Cava Healthcare for the use of psychedelics in treating dementia, including Alzheimer's disease. The deal involves 450,000 common shares at a deemed price of $0.85 each and $120,000 in cash. MYND will also pay a yearly royalty of $240,000 or 4% of net sales. This acquisition aims to strengthen MYND's position in psychedelic treatments for neurodegenerative conditions.
MYND Diagnostics Inc. announced its participation in a proposed clinical trial to evaluate the efficacy of psilocybin-assisted psychotherapy for treatment-resistant depression (TRD). The trial aims to secure a portion of a $15 million fund from the Australian government and will employ MYND's proprietary biomarker technology. Led by Professor Paul Fitzgerald of Monash University, the phase 2b trial will assess the safety and efficacy of psilocybin treatments. If successful, it could lead to a multi-site phase 3 trial for regulatory approval within 12 months.
MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF) will present at the VirtualInvestorConferences.com Psychedelics Conference on October 13, 2021, at 2:00 pm ET. CEO Dr. Lyle Oberg will lead the live, interactive event, allowing investors to ask questions in real-time. A recorded version will be available later for those who cannot attend. Recent company highlights include the launch of MYND Diagnostics Ltd., a $3 million convertible debenture offering, and a publication in The Lancet on Alzheimer's research. Interested investors can register here.
MYND Life Sciences has announced the formation of its diagnostic biomarker division through a wholly-owned subsidiary, MYND Diagnostics Ltd., aimed at enhancing diagnosis and treatment for patients with Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD). The subsidiary plans to generate revenue by Q2 2022 with the commercialization of the MYND Anti-inflammatory Peptide (MAP) biomarker. The global biomarkers market is forecast to grow from USD 41.47 billion in 2019 to USD 115.45 billion by 2027, enhancing MYND Diagnostics' potential in this expanding sector.
MYND Life Sciences Inc. has successfully closed a non-brokered private placement offering, achieving gross proceeds of $2.7 million from the sale of $3 million in convertible debenture units. Each unit comprises $1,000 principal unsecured convertible debentures and warrants to purchase common shares. The debentures bear 5% interest and mature in 24 months with a conversion price set at $0.75 per share. Proceeds will be utilized to advance its drug discovery platform and for general working capital.
MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) has announced a non-brokered private placement offering of debenture units totaling up to $3,000,000. Each debenture unit will consist of senior unsecured convertible debentures and common share purchase warrants. The debentures feature a 5% annual interest and can be converted into shares at $0.75 each. The funds will support the commercialization of its diagnostic division and advance ongoing clinical trials.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announced its eligibility for Depository Trust Company (DTC) services, facilitating easier trading of its stock for US investors. This development enhances MYND's access to US capital markets and could increase liquidity. CEO Dr. Lyle Oberg emphasized the potential for innovation in treating major depressive disorder, noting that 300 million individuals worldwide are underserved by current treatments. The DTC eligibility simplifies trading and settlement processes, positioning MYND for better investor engagement.